Q3 2024 EPS Estimates for Allogene Therapeutics, Inc. (NASDAQ:ALLO) Increased by Analyst

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Equities research analysts at HC Wainwright lifted their Q3 2024 EPS estimates for shares of Allogene Therapeutics in a research note issued on Thursday, August 15th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.30) per share for the quarter, up from their previous forecast of ($0.33). HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.50) per share. HC Wainwright also issued estimates for Allogene Therapeutics’ Q4 2024 earnings at ($0.32) EPS, FY2024 earnings at ($1.32) EPS, Q1 2025 earnings at ($0.33) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.36) EPS and FY2025 earnings at ($1.39) EPS.

Several other equities research analysts also recently weighed in on ALLO. Citigroup upped their target price on shares of Allogene Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Piper Sandler assumed coverage on shares of Allogene Therapeutics in a research note on Friday, May 31st. They set an “overweight” rating and a $11.00 target price on the stock. Canaccord Genuity Group lowered their price target on shares of Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, August 8th. Truist Financial reiterated a “buy” rating and set a $14.00 price target (down previously from $17.00) on shares of Allogene Therapeutics in a report on Friday, August 9th. Finally, Stifel Nicolaus boosted their price target on shares of Allogene Therapeutics from $4.40 to $4.60 and gave the stock a “hold” rating in a report on Tuesday, May 14th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $9.96.

Allogene Therapeutics Stock Down 0.4 %

Shares of ALLO opened at $2.29 on Monday. Allogene Therapeutics has a fifty-two week low of $2.01 and a fifty-two week high of $5.78. The firm’s 50 day moving average price is $2.56 and its 200 day moving average price is $3.36. The company has a market cap of $478.61 million, a P/E ratio of -1.28 and a beta of 0.85.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ALLO. Arizona State Retirement System raised its position in Allogene Therapeutics by 22.2% in the 4th quarter. Arizona State Retirement System now owns 30,458 shares of the company’s stock valued at $98,000 after purchasing an additional 5,543 shares during the last quarter. Vontobel Holding Ltd. raised its position in Allogene Therapeutics by 28.6% in the 4th quarter. Vontobel Holding Ltd. now owns 18,000 shares of the company’s stock valued at $58,000 after purchasing an additional 4,000 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Allogene Therapeutics by 55.4% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,551 shares of the company’s stock valued at $72,000 after purchasing an additional 8,037 shares during the last quarter. Daiwa Securities Group Inc. raised its position in Allogene Therapeutics by 116.3% in the 4th quarter. Daiwa Securities Group Inc. now owns 32,498 shares of the company’s stock valued at $104,000 after purchasing an additional 17,471 shares during the last quarter. Finally, Victory Capital Management Inc. raised its position in Allogene Therapeutics by 23.1% in the 4th quarter. Victory Capital Management Inc. now owns 14,283 shares of the company’s stock valued at $46,000 after purchasing an additional 2,680 shares during the last quarter. Institutional investors and hedge funds own 83.63% of the company’s stock.

Insider Activity

In other news, Director Franz B. Humer sold 11,200 shares of the company’s stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $2.34, for a total value of $26,208.00. Following the completion of the transaction, the director now owns 255,253 shares in the company, valued at approximately $597,292.02. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 24.30% of the company’s stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).